close

Mylan Inc. and its subsidiaries engage in the development, manufacture, marketing, licensing, and distribution of generic, brand, and branded generic pharmaceutical products and active pharmaceutical ingredients (APIs). It operates in three segments: Generics, Specialty, and Matrix. The Generics segment offers generic or branded generic pharmaceutical products in tablet, capsule, or transdermal patch form. This segment markets its products for the proprietary and ethical pharmaceutical wholesalers and distributors, drug store chains, drug manufacturers, institutions, and public and governmental agencies located primarily in the United States, Canada, Europe, the Middle East, Africa, Australia, Japan, and New Zealand. The Specialty segment provides branded specialty nebulized and injectable products for life-threatening conditions. Its principal products comprise EpiPen, used for the treatment of severe allergies; and Perforomist Inhalation Solution, a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disease patients. This segment markets its products to the pharmaceutical wholesalers and distributors located primarily in the United States. The Matrix segment offers APIs and finished dosage forms, as well as distributes branded generic products. It produces APIs for use in the manufacture of its own pharmaceutical products, as well as for use by third-parties, in various categories, including anti-bacterials, central nervous system agents, anti-histamine/anti-asthmatics, cardiovasculars, anti-virals, anti-diabetics, anti-fungals, proton pump inhibitors, and pain management drugs. The Matrix segment also offers anti-retroviral (ARV) APIs used in the treatment of HIV, as well as suppliers generic ARV APIs. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is based in Canonsburg, Pennsylvania.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	22.66
Volume	(mio) 6.19
Volume Avg	(mio) 5.55
52 Week High	25.46
52 Week Low	15.49
PE	18.96
PE (group average)	39
EPS Year	1.22
EPS change Q/Q	2300%
EPS change Q/Q Yr ago	20%
EPS change Q/Q next Q est	-58.62%
EPS change Y/Y	-64.94%
REV change Q/Q	0%
REV change Q/Q Yr ago	0%
EPS next Q est	0.58
EPS next Y est	2.66
Divident Annual	0.00
Dividend Yield	0%